Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, mescaline, DMT +1 moreLSD, mescaline, DMT, other serotonergic psychedelics show less
Psilocybe cubensis
Psilocybe cubensis (magic mushrooms, shrooms) is a psilocybin-producing mushroom in the family Hymenogastraceae — the most widely cultivated psychedelic fungus globally.[1] Its principal active constituent, psilocybin, is converted in the body to psilocin. Psilocin activates serotonin receptors in the prefrontal cortex, disrupting the brain's default network and producing the psychedelic experience.[2]
Psilocybe cubensis (magic mushrooms, shrooms) is a psilocybin-producing basidiomycete fungus in the family Hymenogastraceae and the most widely cultivated psychedelic mushroom species globally.[1] Its principal active constituent, psilocybin, is a tryptamine prodrug converted in the body to psilocin, a partial agonist at serotonin 5-HT₂A receptors. Psilocin produces its psychedelic effects by activating cortical 5-HT₂A receptors, disrupting default mode network connectivity and increasing neural signal entropy.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, mescaline, DMT +1 moreLSD, mescaline, DMT, other serotonergic psychedelics show less
Ceremonial use of psilocybin mushrooms by Mesoamerican peoples dates back at least 3,000 years.[3] R. Gordon Wasson's 1957 publication in Life magazine brought the mushroom to Western attention; Albert Hofmann isolated psilocybin and psilocin the following year.[4] After decades under Schedule I prohibition, clinical research resumed in 2006 and has since produced FDA Breakthrough Therapy designations and regulated therapeutic access in Oregon and Australia.[5]
Subjective effects include brightened colours, flowing visual geometry, heightened emotional sensitivity, thought connectivity, and — at higher doses — ego dissolution and mystical-type experiences. The experience is characteristically introspective and body-centred, shaped powerfully by mindset and environment.[6] Unwanted effects include nausea at onset, acute anxiety and panic reactions, and transient confusion.
Psilocybin produces no physical dependence and no withdrawal, and no human fatalities from psilocybin toxicity alone are documented.[7] The primary dangers are psychological — acute anxiety reactions and, rarely, lasting psychosis in people with a personal or family history of psychotic disorders. Potency varies 2–4-fold between individual fruiting bodies even within a single batch,[8] making dose prediction difficult with uncharacterised material.
History[edit]
Traditional and historical use
Archaeological evidence places ceremonial psilocybin mushroom use in Mesoamerica at least 3,000–3,500 years in the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from around 1000 BCE to 900 CE.[3] The Mazatec people of Oaxaca used psilocybin mushrooms — called teonanácatl ("flesh of the gods" in Nahuatl) — in the Velada, a nocturnal healing ceremony guided by a curandera. Scholarly documentation of indigenous practices spans anthropology, archaeology, ethnolinguistics, and ethnomycology.[9]
Western discovery and research
R. Gordon Wasson participated in a Mazatec Velada ceremony with the curandera María Sabina in 1955 and published his account in Life magazine in 1957 — the first major Western public exposure to psilocybin mushrooms.[10] Roger Heim collected and identified the specimens; Albert Hofmann at Sandoz Laboratories isolated psilocybin and psilocin in 1958.[4]
Modern era
Psilocybin was classified as Schedule I in the US in 1970, and the 1971 UN Convention listed psilocybin and psilocin — though the mushrooms themselves were not explicitly named.[11] Research effectively halted for three decades until a 2006 Johns Hopkins trial showed psilocybin reliably occasioned meaningful mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences.[5] Subsequent milestones include FDA Breakthrough Therapy designations for depression, Oregon's regulated psilocybin services framework (first centres opened 2023), and Australia's rescheduling to permit psychiatric prescribing.[12]
The Mazatec Velada is a nocturnal healing ceremony in which a curandera ingests psilocybin mushrooms and channels the experience to diagnose or treat illness. The mushrooms were called nti si tho in Mazatec. María Sabina, the curandera who shared the ceremony with Wasson, later expressed regret at the cultural disruption that followed Western publication. Scholarly documentation of indigenous psilocybin practices spans multiple disciplines.[9]
Botanical Overview[edit]
Psilocybe cubensis (Earle) Singer belongs to the family Hymenogastraceae. First described as Stropharia cubensis by Franklin Sumner Earle in 1906 from Cuban specimens,[13] it was transferred to Psilocybe by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph on the genus remains the authoritative taxonomic treatment.[14]
P. cubensis is a subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, growing vigorously on simple substrates and tolerating variable conditions.
The mature cap is convex to broadly umbonate, 2–8 cm across, ranging from pale golden to caramel brown with a darker centre. The stipe is whitish and bruises blue-green when damaged — the hallmark bluing reaction of psilocybin-containing tissue. The critical identification risk for wild foragers is confusion with Galerina marginata, which contains lethal amatoxins.[15] The most reliable discriminators are spore print colour (purplish-black for Psilocybe, rusty-brown for Galerina) and the bluing reaction. Fruiting bodies are typically dried for storage; 1 g dried corresponds to roughly 10 g fresh.
Alkaloid Profile[edit]
The dominant psychoactive compound in P. cubensis is psilocybin — a tryptamine prodrug rapidly converted in the body to psilocin by alkaline phosphatases.[16] Psilocin is the active molecule, acting primarily on serotonin receptors in the prefrontal cortex.[2] Dried fruiting bodies typically contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens.
The mushroom also contains β-carboline alkaloids that inhibit MAO-A (MAO-A) — an enzyme involved in breaking down psilocin.[17] These β-carbolines may extend psilocin's effects in whole-mushroom preparations compared to synthetic psilocybin, though this has not been confirmed in human studies.[18] Minor alkaloids — baeocystin, norbaeocystin, and aeruginascin — are present at lower concentrations; their individual contributions to the experience are poorly understood. Psilocybin's oral bioavailability is approximately 52.7%, peaking in the bloodstream 1.8–4 hours after ingestion.[19]
Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch.[8] Growing conditions, substrate composition, harvest timing, and cultivar all influence potency. This variability is the primary obstacle to accurate dose prediction with uncharacterised mushroom material.
Neuroscience[edit]
Where it acts
Psilocin crosses the blood-brain barrier and activates serotonin receptors concentrated in pyramidal neurons of the prefrontal cortex — the primary mechanism underlying psychedelic effects.[2] It also engages serotonin receptors linked to calming inhibitory signals,[20] and activates a receptor that promotes neuroplasticity — changes in brain connectivity that may persist well beyond the acute experience.[2]
What it changes
The REBUS model proposes that psilocin loosens the brain's top-down predictions, letting raw sensory input drive experience more strongly and increasing the variability of brain signals.[21] A single 25 mg dose disrupted brain functional connectivity more than threefold compared to methylphenidate in precision brain imaging, with the strongest effects in the default mode network — the system linked to self-referential thought. A decrease in one key connectivity measure persisted for three weeks after the session.[22]
- Whole-mushroom pharmacokinetics versus synthetic psilocybin in humans remain uncharacterised.
- The contribution of CYP2D6 genetic polymorphisms to interindividual variability in psilocybin response has not been established in a genotype-stratified study.
- Whether endogenous β-carbolines in mushroom preparations alter clinical outcomes relative to synthetic psilocybin is unknown.
Subjective Effects[edit]
The P. cubensis experience is characteristically introspective and body-centred — a sense of emotional proximity, bodily weight, and perceptual richness that users frequently describe as "earthy." Effects are powerfully shaped by mindset and environment.[6] Low doses produce mood lift and subtle perceptual shifts; moderate doses introduce flowing visual geometry and thought connectivity; high doses can produce full ego dissolution and mystical-type experiences.
Compared to LSD, P. cubensis produces a shorter arc with a more emotional, body-centred character and less visual architecture. Compared to synthetic psilocybin administered in clinical settings, whole-mushroom preparations introduce multi-alkaloid composition and uncontrolled potency,[18] which may explain the wider range of intensities reported at ostensibly equivalent doses.
Ceremonial use of psilocybin mushrooms by Mesoamerican peoples dates back at least 3,000 years.[3] R. Gordon Wasson's participation in a Mazatec ceremony in 1955 brought the species to Western attention; Albert Hofmann isolated psilocybin and psilocin in 1958. After decades under Schedule I prohibition, a landmark 2006 controlled trial reignited clinical investigation,[4] leading to FDA Breakthrough Therapy designations and regulated therapeutic frameworks in Oregon and Australia.
Subjective effects span visual geometry and color enhancement, thought connectivity and introspection, emotional lability, and ego dissolution or mystical-type experiences. The experience is characteristically introspective and somatically grounded, lasting 4–8 hours with dried oral preparations.[5] Unsought effects include acute anxiety and panic reactions, nausea, and transient confusion — strongly modulated by set and setting.[6]
Psilocybin produces no physical dependence and no withdrawal; rapid tolerance via 5-HT₂A downregulation limits compulsive use.[7] The primary risks are psychological — acute anxiety reactions and, rarely, persisting psychosis in predisposed individuals — rather than physiological, as no human fatalities from psilocybin toxicity alone are documented.[7] Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single batch,[8] complicating dose prediction for uncharacterized material.
History[edit]
Traditional and historical use
Archaeological evidence places ceremonial psilocybin mushroom use by Mesoamerican indigenous peoples at least 3,000–3,500 years into the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from approximately 1000 BCE to 900 CE.[3] The Mazatec people of Oaxaca, Mexico are the best-documented practitioners, using psilocybin mushrooms — called teonanácatl (Nahuatl: "flesh of the gods") — in the Velada, a nocturnal healing ceremony guided by a curandera or curandero. An annotated bibliography spanning 49 scholarly works documents indigenous psilocybin practices across anthropology, archaeology, ethnolinguistics, and ethnomycology.[9]
Western discovery and research
R. Gordon Wasson, an amateur mycologist and J.P. Morgan vice president, participated in a Mazatec Velada ceremony with the curandera María Sabina in 1955 and published his account in Life magazine in May 1957 — the first major Western public exposure to psilocybin mushrooms.[10] Roger Heim collected and identified the specimens, and Albert Hofmann at Sandoz Laboratories isolated and characterized psilocybin and psilocin in 1958, naming both compounds after the Psilocybe genus.[11]
Modern era
Psilocybin was classified as Schedule I under the U.S. Controlled Substances Act in 1970, and the 1971 UN Convention on Psychotropic Substances listed psilocybin and psilocin as Schedule I — though psilocybin mushrooms themselves were not explicitly named in the Convention text.[12] Research effectively ceased for three decades until a 2006 double-blind study at Johns Hopkins demonstrated that psilocybin reliably occasioned mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences.[4]
Subsequent milestones include FDA Breakthrough Therapy designations for treatment-resistant depression (2018) and major depressive disorder (2019), Oregon's regulated psilocybin services framework (first centres opened 2023), Colorado's decriminalization of personal use (2022), and Australia's TGA rescheduling to Schedule 8 for authorised psychiatric prescribing.[13]
The Mazatec Velada is a nocturnal healing ceremony in which a curandera ingests psilocybin mushrooms and channels the experience to diagnose or treat illness. The mushrooms were called nti si tho in Mazatec. María Sabina, the curandera who shared the ceremony with Wasson, later expressed regret at the cultural disruption that followed Western publication. Scholarly documentation of indigenous psilocybin practices spans multiple disciplines.[9]
Botanical Overview[edit]
Psilocybe cubensis (Earle) Singer belongs to the family Hymenogastraceae. First described as Stropharia cubensis by Franklin Sumner Earle in 1906 from Cuban specimens,[14] the species was transferred to Psilocybe by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph The Genus Psilocybe remains the authoritative taxonomic treatment, describing approximately 144 species at publication.[15]
P. cubensis is a coprophilic, subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, owing to vigorous growth on simple substrates (brown rice flour, vermiculite, pasteurised grain) and tolerance of variable growing conditions.
The mature fruiting body has a convex to broadly umbonate cap, 2–8 cm in diameter, ranging from pale golden to caramel brown and often developing a darker centre. The stipe is 4–15 cm long, whitish, and bruises blue-green when damaged — a hallmark bluing reaction indicating psilocybin-containing tissue. The spore print is purplish-black to dark brown. The critical identification concern for wild foragers is distinguishing Psilocybe from the hepatotoxic Galerina marginata, which contains lethal amatoxins.[16] The most reliable field-level discriminators are spore print colour (purplish-black for Psilocybe versus rusty-brown for Galerina) and the presence of the bluing reaction on damaged tissue.
Fruiting bodies are typically harvested just before or shortly after the veil breaks and dried for storage. Drying preserves alkaloid content for months to years. Fresh mushrooms contain approximately 90% water by weight, so 1 g dried material corresponds to roughly 10 g fresh.
Alkaloid Profile[edit]
The dominant psychoactive constituent of P. cubensis is psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), a tryptamine prodrug rapidly dephosphorylated in the body to psilocin (4-hydroxy-N,N-dimethyltryptamine) by alkaline phosphatases.[17] Psilocin is the pharmacologically active molecule, acting primarily as a partial agonist at 5-HT₂A serotonin receptors.[2] Typical dried P. cubensis fruiting bodies contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens.
The mushroom matrix delivers psilocybin alongside endogenous β-carboline alkaloids that function as MAO-A (MAO-A) inhibitors.[18] Because MAO-A participates in psilocin degradation, these β-carbolines may extend psilocin's effective duration in whole-mushroom preparations relative to synthetic psilocybin. This "entourage" interaction is supported by preclinical evidence[19] but has not been quantified in human pharmacokinetic studies.
Minor alkaloids identified in P. cubensis include baeocystin (norpsilocybin), norbaeocystin, and aeruginascin — structurally related tryptamines present at lower concentrations. Their individual contributions to the subjective experience remain poorly characterised, with existing data limited to in vitro studies and anecdotal reports.
Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch.[8] Factors influencing potency include substrate composition, growing conditions, harvest timing, and the specific cultivar or genetic lineage. This variability is the primary obstacle to dose standardisation when using uncharacterised mushroom material.
Psilocybin's oral bioavailability is approximately 52.7%, with psilocin reaching peak plasma concentration (tmax) at 1.8–4 hours and an half-life of 1.5–4 hours.[20] Metabolism proceeds primarily via CYP2D6 and CYP3A4, with secondary MAO-A contribution.[17]
Neuroscience[edit]
Where it acts
Psilocin crosses the blood-brain barrier and binds 5-HT₂A receptors concentrated in pyramidal neurons of the prefrontal cortex — the primary mechanism underlying psychedelic effects.[2] Additional engagement of 5-HT₁A receptors contributes to synaptic depression via enhanced GABAergic signalling,[21] while direct activation of TrkB (BDNF) receptors may explain neuroplastic effects persisting well beyond acute drug activity.[2]
What it changes
The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psilocin loosens top-down cortical predictions, allowing greater bottom-up sensory influence and increasing entropy in brain signals.[22] Precision fMRI tracking of individual brains found that a single 25 mg psilocybin dose disrupted functional connectivity more than threefold compared to methylphenidate, with the strongest effects in the default mode network. A persistent decrease in hippocampal-default mode network connectivity lasted three weeks post-session — hypothesised as a neuroanatomical correlate of psilocybin's pro-plasticity and therapeutic effects.[23]
- Whole-mushroom pharmacokinetics versus synthetic psilocybin in humans remain uncharacterised.
- The contribution of CYP2D6 genetic polymorphisms to interindividual variability in psilocybin response has not been established in a genotype-stratified study.
- Whether endogenous β-carbolines in mushroom preparations alter clinical outcomes relative to synthetic psilocybin is unknown.
Subjective Effects[edit]
The P. cubensis experience is characteristically introspective and somatically grounded — a sense of bodily weight, emotional proximity, and perceptual richness that users frequently describe as "earthy" relative to the more visually architectural character of LSD. Effects are powerfully shaped by set and setting; the same dose in a supportive environment versus an unfamiliar social context can produce qualitatively different experiences.[6] Across the dose range, low doses produce mood lift and subtle perceptual shifts, moderate doses introduce flowing visual geometry and thought connectivity, and high doses can produce full ego dissolution and mystical-type experiences.
Compared to LSD, P. cubensis produces a shorter arc — 4–8 hours versus 8–12 — with a more emotional and body-centred character. Compared to synthetic psilocybin administered in clinical settings, whole-mushroom preparations introduce the variable of multi-alkaloid composition and uncontrolled potency, which may contribute to the wider range of subjective intensities reported at ostensibly equivalent doses.[19]
Effect Grid
Full psychedelic experience — open-eye visual distortions including visual breathing, visual drifting, and mild geometry are characteristic. Color enhancement is pronounced. Closed-eye internal hallucinations produce vivid imagery. Time alteration is prominent, with minutes feeling stretched or compressed. Thought connectivity deepens, introspection enhancement intensifies, and emotional enhancement can shift rapidly between euphoria, anxiety, and catharsis.
Nausea is common during onset, often accompanied by yawning and occasional muscle tension. Body high becomes a distinct feature. Pupil dilation is marked. Headache and dizziness are reported in clinical settings as the most frequent adverse events.
Social interaction is possible but altered. Confusion and thought disorganization may occur in waves. This range encompasses most clinical trial doses (equivalent to approximately 10–25 mg synthetic psilocybin). Duration is typically 4–8 hours. Alkaloid variability means a "standard" 3.5 g dose corresponds to roughly 17–35 mg psilocybin equivalent.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Holotropic state · Brightness alteration · Depth perception distortion · Environmental patterning · Music enhancement · Perspective distortion · Sound sensitivity · Tracers · Visual morphing · After-images · Auditory distortion · Auditory enhancement · Light sensitivity · Proprioceptive distortion · Symmetrical texture repetition · Visual haze / noise · Ganzfeld effect · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Visual melting · Dreaming enhancement · Peripheral misidentification · Sleep-transition hallucinations · Synesthesia · Vestibular distortion · Visual acuity enhancement · Visual diffraction · Visual magnification · Visual processing acceleration · Visual acuity suppression · Flashbacks · Internal hallucinations · Object transformations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Shadow people · Persisting hallucinations
Environmental patterning · Music enhancement · Perspective distortion · Sound sensitivity · Tracers · Visual morphing · After-images · Auditory distortion · Auditory enhancement · Light sensitivity · Proprioceptive distortion · Symmetrical texture repetition · Visual haze / noise · Ganzfeld effect · Auditory misinterpretation · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Visual melting · Dreaming enhancement · Peripheral misidentification · Sleep-transition hallucinations · Synesthesia · Vestibular distortion · Visual acuity enhancement · Visual diffraction · Visual magnification · Visual processing acceleration · Visual acuity suppression · Flashbacks · Internal hallucinations · Object transformations · Visual recursion · Environmental orbism / cubism · External hallucinations · Object activation · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Shadow people · Persisting hallucinations
Body schema distortion · Laughter fits · Nausea · Spontaneous body sensations · Wakefulness · Appetite suppression · Dizziness · Heart rate perception changes · Physical fatigue · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Bodily heaviness · Bodily lightness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Muscle relaxation · Restlessness · Tactile euphoria · Abnormal heartbeat · Headache · Insomnia · Muscle tension · Nystagmus (eye wobbles) · Sedation · Trembling · Diarrhea · Involuntary body movements · Pain suppression · Vasoconstriction · Vomiting · Bodily dissociation · Tactile hallucination
Spontaneous body sensations · Wakefulness · Appetite suppression · Dizziness · Heart rate perception changes · Physical fatigue · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Bodily heaviness · Bodily lightness · Bodily pressures · Breathing alteration · Dry mouth · Excessive sweating · Muscle relaxation · Restlessness · Tactile euphoria · Headache · Insomnia · Muscle tension · Nystagmus (eye wobbles) · Sedation · Trembling · Diarrhea · Involuntary body movements · Pain suppression · Vasoconstriction · Vomiting · Bodily dissociation · Tactile hallucination
Conceptual thinking · Immersion enhancement · Openness enhancement · Thought connectivity · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Increased nature relatedness · Multiple thought streams · Pattern recognition enhancement · Cognitive fatigue · Confusion · Focus suppression · Memory fragmentation · Memory replays · Synchronicity · Thought acceleration · Thought disorganization · Thought loops · Analysis enhancement · Creativity enhancement · Humor enhancement · Analysis suppression · Cognitive dysphoria · Information processing suppression · Language suppression · Memory suppression · Information processing enhancement · Motivation enhancement · Motivation suppression · Thought deceleration · Focus enhancement · Delusions · Amnesia · Delirium
Thought connectivity · Cognitive euphoria · Cognitive flexibility · Cognitive impairment · Increased nature relatedness · Multiple thought streams · Pattern recognition enhancement · Cognitive fatigue · Confusion · Focus suppression · Memory fragmentation · Memory replays · Synchronicity · Thought acceleration · Thought disorganization · Thought loops · Analysis enhancement · Creativity enhancement · Humor enhancement · Analysis suppression · Cognitive dysphoria · Information processing suppression · Language suppression · Memory suppression · Information processing enhancement · Motivation enhancement · Motivation suppression · Thought deceleration · Focus enhancement · Amnesia · Delirium
Anxiety · Catharsis · Empathy enhancement · Euphoria · Anxiety suppression · Dysphoria · Irritability
Anxiety suppression · Dysphoria · Irritability
Disinhibition · Trust enhancement · Compulsive behavior reduction · Sociability enhancement · Communication enhancement · Flow state · Automaticity · Communication suppression · Sociability suppression · Social disconnection · Ego inflation · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution · Telepathic feelings
Communication enhancement · Flow state · Automaticity · Communication suppression · Sociability suppression · Social disconnection · Ego inflation · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution · Telepathic feelings
Time cessation
Transpersonal memory access · Transpersonal visions · Cessation · Death-rebirth sequence · Entity contact · Voidness · Near-death experience
Entity contact · Voidness · Near-death experience
Lucidity enhancement · Recursive awareness
Timeline · by preparation
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DMT
Toxicity
Psilocybin has low acute physiological toxicity — no human fatalities from psilocybin toxicity alone are documented,[7] and the therapeutic index is extremely high relative to typical human doses.[4] In clinical trials, the most common adverse events were headache, nausea, and dizziness.[23][24] Cardiovascular effects are generally mild and transient; insufficient data exist on safety in patients with established cardiovascular disease.[25]
Wild foraging carries risk of fatal misidentification with Galerina marginata, which contains lethal amatoxins.[15] Products sold as psilocybin may be adulterated — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich reagent testing confirms indole presence but cannot identify all synthetic imposters; definitive identification requires GC-MS or LC-MS/MS.[26] Cultivated mushrooms are susceptible to mould contamination.safety citation needed
Psychological Risks
The most common adverse psychological event is an acute anxiety reaction — intense fear, paranoia, panic, and confusion.[7] Risk is dose-dependent and context-dependent, reduced by supportive set and setting.[6]
Persisting psychosis is rare but documented, primarily in people with a personal or family history of psychotic disorders.[7]
Persistent visual disturbances — geometry, halos, trails, and visual haze / noise — can continue after use ceases, a condition known as HPPD (HPPD).[27] HPPD has been documented in adolescents[28] and adults; precise prevalence estimates remain unavailable.
Tolerance & Dependence
Psilocybin builds tolerance rapidly via serotonin downregulation; consecutive-day dosing produces substantially diminished effects. Clinical protocols space sessions 1–4 weeks apart. Cross-tolerance with LSD and other serotonergic psychedelics is established.[7]
Psilocybin produces no physical dependence and no clinically recognised withdrawal syndrome.[7][29] A systematic review of psilocybin for substance use disorders found no addiction signals.[30]
Drug Interactions
MAOIs + psilocybin mushrooms: Hypertensive emergency has been documented in case reports.[31] MAOIs combined with the mushroom's own monoamine oxidase-inhibiting compounds severely impair serotonin breakdown, amplifying serotonergic and cardiovascular effects.[17] This combination should be avoided.
SSRIs: Long-term SSRI use blunts subjective psychedelic effects. No serotonin syndrome cases from SSRI + psilocybin have been documented in the peer-reviewed literature.[32]
Lithium: Potentially hazardous; proposed mechanisms include serotonergic amplification and pro-convulsant effects.[7]safety citation needed
Cannabis: May add to anxiety and paranoia and intensify subjective effects. No specific pharmacokinetic interaction is documented.
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine): may prolong psilocin exposure by impairing its primary metabolic pathway.[16]
Contraindications
Absolute contraindications:
- Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): psilocybin may precipitate or worsen psychosis.[7]
- Concurrent MAOI use: risk of hypertensive emergency.[31]
Relative contraindications:
- Active suicidal ideation: exclusion criterion in clinical trials.[23]
- Cardiovascular disease: insufficient safety data.[25]
- Concurrent lithium therapy: potential seizure risk.[7]safety citation needed
- Hepatic impairment: metabolism may be slowed, prolonging psilocin exposure. No published data exist.
- Pregnancy: no human safety or teratogenicity data.safety citation needed
- Adolescents and minors: no clinical trials; HPPD documented in a 16-year-old.[28]
Preparations[edit]
Dried whole mushrooms (oral)
Dried whole mushrooms are the most common preparation. Fruiting bodies are dehydrated and consumed directly or mixed with food. Threshold: 0.25–0.5 g; common: 1–2.5 g; strong: 3–5 g. Onset: 20–60 minutes. Duration: 4–6 hours. Nausea is frequent at onset, particularly on a full stomach. Potency varies 2–4-fold between individual fruiting bodies,[8] making precise dosing difficult with uncharacterised material.
Mushroom tea (oral)
Mushroom tea is made by steeping chopped or ground dried mushrooms in hot (not boiling) water for 10–20 minutes, then straining. Dose ranges are equivalent to dried whole mushrooms by starting weight. Onset is faster (15–30 minutes). Duration may be slightly shorter (3–5 hours). Straining removes chitin and reduces nausea for many users.
Lemon tek (oral)
Lemon tek involves soaking finely ground dried mushroom material in lemon or lime juice for 15–20 minutes before consuming the liquid. The acidic environment accelerates conversion of psilocybin to psilocin, producing faster onset (10–20 minutes), a more compressed and often more intense experience, and shorter total duration (3–4 hours). Dose ranges by weight are equivalent to dried mushrooms; the compressed timeline raises the risk of overwhelming intensity at usual dose amounts.
Capsules (oral)
Capsules contain measured amounts of dried, ground mushroom material, offering more consistent dosing than whole fruiting bodies. Microdose capsules typically contain 0.05–0.3 g, intended for sub-perceptual effects on a schedule. Full-dose capsules follow the same dose ranges as dried whole mushrooms. Onset and duration are comparable to dried mushroom ingestion.
Fresh mushrooms (oral)
Fresh mushrooms contain approximately 90% water by weight — roughly 10 g fresh corresponds to 1 g dried. Onset and duration are similar to dried preparations. Fresh material degrades rapidly without refrigeration.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
Lab testing is the only reliable method to confirm that a mushroom product contains psilocybin and is free of contaminants or adulterants. Ehrlich reagent testing confirms indole alkaloid presence (purple/violet reaction) but cannot distinguish psilocybin from all synthetic indoles — a positive result is necessary but not sufficient.
For whole dried mushrooms, the bluing reaction on damaged tissue and a purplish-black spore print are the most reliable field indicators of Psilocybe species. Misidentification with Galerina marginata — rusty-brown spore print, lethal amatoxin content — is the primary physical safety risk of wild foraging.
Guidelines
Practical guidance
- Start low. Begin with 0.5–1 g dried mushroom material for a first experience. Increase only after assessing individual sensitivity.
- Weigh the dose. Use a digital scale accurate to 0.1 g. Do not estimate by visual size — potency varies 2–4-fold between individual fruiting bodies.
- Allow time. Onset takes 20–60 minutes (faster with tea or lemon tek). Do not redose before 90 minutes.
- Eat lightly beforehand. A light meal 2–3 hours before reduces nausea without significantly delaying onset.
- Prepare the environment. Remove hazards. Have water, comfortable seating, blankets, calming music, and a phone accessible.
- Plan the time. Block 6–8 hours with no obligations. Do not drive or operate machinery.
- Avoid dangerous combinations. Do not combine with MAOIs, lithium, or cannabis (especially for inexperienced users). Review Drug Interactions in the Safety section.
- Test the material. Use Ehrlich reagent at minimum. For commercial products, request or verify Certificate of Analysis where available.
Set & Setting
Set (mindset) and setting (environment) influence psilocybin experiences as powerfully as dose itself.[6] A familiar, physically safe, comfortable environment with minimal unexpected stimulation reduces risk. Use during periods of acute psychological distress, unresolved grief, or high anxiety elevates the risk of difficult experiences.
A trusted, sober companion ("trip sitter") substantially reduces risk, especially for inexperienced users or higher doses. The sitter's role is to provide calm reassurance, not to direct the experience. Clinical protocols universally include trained support personnel for this reason.
Aftercare & integration.
Post-experience processing
The hours and days following a psilocybin experience often include emotional sensitivity, fatigue, and a reflective mood. This is normal and typically resolves within 24–48 hours.
- Hydrate and eat. Appetite may be suppressed during the experience. Rehydrate and consume a balanced meal afterward.
- Rest. Sleep may be disrupted the night of the experience. Allow extra rest the following day.
- Reflect, don't react. Significant experiences may provoke strong feelings or insights. Journaling or talking with a trusted person helps integration. Avoid major life decisions in the immediate aftermath.
- Monitor mood. If persistent anxiety, depersonalisation, or visual disturbances arise, consult a healthcare professional.
Recovery & Support
Cessation and support resources
Psilocybin does not produce physical dependence or withdrawal. Patterns of repeated use that interfere with daily functioning warrant attention and support.
- SAMHSA National Helpline: 1-800-662-4357 (US) — free, confidential, 24/7 referral service.
- Fireside Project: 62-FIRESIDE (623-473-7433) — psychedelic peer support line.
- Crisis Text Line: Text HOME to 741741 (US).
- Integration therapists: Directories at MAPS (maps.org) and Psychedelic.Support list therapists experienced in psychedelic integration.
- Tolerance management: Psilocybin's rapid tolerance (full reset in approximately 10–14 days) naturally limits frequent use. If using more often than every two weeks, consider whether the pattern serves a constructive purpose.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising and responding to a crisis
Recognise an emergency:
- Severe, escalating panic or paranoia unresponsive to reassurance
- Psychotic symptoms: delusions, loss of contact with reality, self-harm impulses
- Seizures or loss of consciousness
- Chest pain or difficulty breathing
- Suicidal statements or actions
Immediate steps:
- 1. Stay with the person. Do not leave them alone.
- 2. Speak calmly and simply: "You are safe. You took a mushroom. The effects are temporary."
- 3. Move them to a quiet, low-stimulation space if possible.
- 4. If they are overheating, cool them with water and airflow.
- 5. Call emergency services (911 / 112 / local equivalent) if: seizures occur, breathing is compromised, psychotic symptoms are severe, or the person is at risk of harming themselves or others.
What to tell the dispatcher:
- "They ingested psilocybin mushrooms" — name the substance.
- Approximate amount and time of ingestion.
- Current symptoms.
- Good Samaritan laws in many jurisdictions protect callers reporting drug emergencies from prosecution.
There is no pharmacological reversal agent for psilocybin. Benzodiazepines may be administered by medical professionals to manage severe anxiety or agitation. Time is the primary resolution — acute effects resolve within 4–8 hours.
Legal Status[edit]
Psilocybin and psilocin are scheduled under the 1971 UN Convention on Psychotropic Substances — though psilocybin mushrooms themselves were not explicitly named in the treaty.[11] This ambiguity has allowed some jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. In the United States, psilocybin and psilocin are Schedule I under federal law, with a rescheduling petition pending as of 2025; Oregon operates a regulated therapeutic access framework (first centres opened 2023); Colorado has decriminalised personal use for adults; and several cities — including Oakland, Santa Cruz, Ann Arbor, and Seattle — have passed local deprioritisation measures.[11] In the United Kingdom, psilocybin is Class A — the most severe penalty category.[11] Australia rescheduled psilocybin in 2023 to permit prescribing by authorised psychiatrists for treatment-resistant depression.[12] The Netherlands prohibits dried mushrooms but permits psilocybin-containing truffles; Canada permits access via exemption for palliative care and therapist training. The legal landscape is shifting rapidly across many jurisdictions.
Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information.
Preparations[edit]
Dried whole mushrooms (oral)
Dried whole mushrooms are the most common preparation. Fruiting bodies are dehydrated and consumed directly or mixed with food. Threshold: 0.25–0.5 g dried; common: 1–2.5 g dried; strong: 3–5 g dried. Onset: 20–60 minutes. Duration: 4–6 hours. Nausea is frequent at onset, particularly on a full stomach. Potency varies 2–4-fold between individual fruiting bodies,[8] making precise dosing difficult with uncharacterised material.
Mushroom tea (oral)
Mushroom tea is prepared by steeping chopped or ground dried mushrooms in hot (not boiling) water for 10–20 minutes, then straining. Dose ranges are equivalent to dried whole mushrooms by weight of starting material. Onset is typically faster (15–30 minutes) due to aqueous extraction of psilocybin. Duration may be slightly shorter (3–5 hours). The straining step reduces chitin-related nausea for many users.
Lemon tek (oral)
Lemon tek involves soaking finely ground dried mushroom material in lemon or lime juice for 15–20 minutes before consumption. The acidic environment is reported to accelerate dephosphorylation of psilocybin to psilocin, producing a faster onset (10–20 minutes) and a more compressed, often more intense experience with a shorter total duration (3–4 hours). Dose ranges by weight are equivalent to dried mushrooms, but the compressed timeline increases the risk of overwhelming intensity — starting at the lower end of one's usual dose range is advisable.
Capsules and microdose preparations (oral)
Capsules contain measured amounts of dried, ground mushroom material, offering more consistent dosing than whole fruiting bodies. Microdose capsules typically contain 0.05–0.3 g dried material, intended for sub-perceptual effects taken on a schedule (e.g., one day on, two days off). Full-dose capsules follow the same dose ranges as dried whole mushrooms. Onset and duration are comparable to dried mushroom ingestion.
Fresh mushrooms (oral)
Fresh mushrooms contain approximately 90% water by weight, so roughly 10 g fresh corresponds to 1 g dried. They are consumed directly or blended into smoothies. Onset and duration are similar to dried preparations. Fresh material degrades rapidly if not refrigerated.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DMT
Toxicity
Psilocybin has low acute physiological toxicity. No human fatalities from psilocybin toxicity alone are documented in the peer-reviewed literature.[7] The therapeutic index is extremely high relative to typical human doses.[11]
In clinical trials, adverse events are frequent but predominantly transient and self-limiting. The largest Phase 2 trial (233 participants with treatment-resistant depression) reported adverse events in 77% of participants — most commonly headache, nausea, and dizziness.[24] A Phase 2 RCT of 25 mg psilocybin for major depressive disorder found no serious treatment-emergent adverse events.[25]
Cardiovascular effects are generally mild and transient, including modest increases in blood pressure and heart rate. Insufficient data exist on psilocybin safety in patients with established cardiovascular disease.[26]
Standard workplace urine drug screens do not reliably detect psilocin, with approximately 1.3% cross-reactivity on amphetamine/methamphetamine assays.[27][28] Confirmatory GC-MS or LC-MS/MS is required for definitive identification. Psilocin is detectable in urine for approximately 24–72 hours after ingestion.
Contaminant and adulterant risks: Wild-harvested mushrooms carry the primary danger of misidentification with hepatotoxic species, particularly Galerina marginata (amatoxin-containing), which can be fatal.[16] Commercially obtained products sold as psilocybin may be adulterated with synthetic substances — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich reagent testing produces a purple/violet reaction confirming indole presence but does not rule out all synthetic imposters; definitive identification requires GC-MS or LC-MS/MS.[27]
Cultivated mushrooms are susceptible to mould contamination (Trichoderma spp., cobweb mould), implying potential mycotoxin exposure.safety citation needed No ISO/IEC-accredited lab testing programs or Certificate of Analysis requirements currently apply to psilocybin mushroom products in any jurisdiction with regulated access.
Psychological Risks
The most common adverse psychological event is the acute anxiety reaction — an overwhelming experience characterised by intense anxiety, fear, paranoia, panic, and dysphoric confusion.[7] This risk is dose-dependent and context-dependent, mitigated by appropriate set, setting, and interpersonal support.[6]
Persisting psychosis is rare but documented, primarily in individuals with personal or family history of psychotic disorders. This is the principal screening contraindication in all clinical research protocols.[7]
Hallucinogen persisting perception disorder (HPPD) involves persistent visual disturbances — geometry, halos, trails, visual haze / noise — continuing after use ceases. Psilocybin and LSD are the most commonly reported precipitants.[29] HPPD has been documented in adolescents[30] and adults; precise prevalence estimates remain unavailable.
Tolerance & Dependence
Psilocybin produces rapid tachyphylaxis via 5-HT₂A downregulation. Consecutive-day dosing produces substantially diminished effects; clinical protocols space sessions by 1–4 weeks. Cross-tolerance with LSD and other serotonergic psychedelics is established.[7]
Psilocybin produces no physical dependence and no clinically recognised withdrawal syndrome.[7][31] The DSM-5 does not include a hallucinogen withdrawal. A systematic review of psilocybin for substance use disorders found no addiction signals.[32]
Drug Interactions
MAOI + psilocybin mushrooms: Hypertensive emergency has been documented in case reports.[33] Exogenous MAOIs combined with endogenous β-carboline monoamine oxidase inhibitors in the mushroom matrix[18] severely impair serotonin metabolism, potentiating both serotonergic and sympathomimetic effects. This combination should be avoided.
SSRIs: Long-term SSRI use is associated with blunted subjective psychedelic effects, likely via 5-HT₂A receptor downregulation. A post-hoc analysis found that antidepressant discontinuation prior to psilocybin did not significantly affect clinical outcomes in treatment-resistant depression.[34] No serotonin syndrome cases from SSRI + psilocybin have been documented in the peer-reviewed literature.
Lithium: The lithium + psilocybin combination is flagged as potentially hazardous, with proposed mechanisms including serotonergic amplification and lithium's pro-convulsant effects.[7] safety citation needed
Cannabis: Additive effects on anxiety and paranoia have been reported. Co-administration may intensify subjective effects. No specific pharmacokinetic interaction is documented.
CYP2D6 inhibitors: Drugs inhibiting CYP2D6 (fluoxetine, paroxetine, bupropion, quinidine) may prolong psilocin exposure by impairing its primary metabolic pathway.[17]
Contraindications
Absolute contraindications:
- Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features): psilocybin may precipitate or exacerbate psychosis. This is the primary exclusion criterion in all clinical research protocols.[7]
- Concurrent MAOI use: risk of hypertensive emergency.[33]
Relative contraindications:
- Active suicidal ideation: exclusion criterion in clinical trials.[24]
- Cardiovascular disease: insufficient safety data in patients with established cardiovascular disease.[26]
- Concurrent lithium therapy: potential seizure risk.[7] safety citation needed
- Hepatic impairment: CYP2D6/CYP3A4 metabolism may be impaired, prolonging psilocin exposure. No published data exist.
- Pregnancy: no human safety or teratogenicity data. safety citation needed
- Adolescent and pediatric populations: no clinical trials in minors; HPPD documented in a 16-year-old.[30]
Harm Reduction[edit]
Forms & Identification
Lab testing is the only reliable method to confirm that a mushroom product contains psilocybin and is free of contaminants or adulterants. Ehrlich reagent testing confirms indole alkaloid presence (purple/violet reaction) but cannot distinguish psilocybin from all synthetic indoles — a positive Ehrlich result is necessary but not sufficient. For pressed tablets, capsules, or powders sold as "psilocybin," reagent testing is especially important: NBOMe-series compounds and other research chemicals have been detected in products marketed as psilocybin mushrooms.
For whole dried mushrooms, identification skill matters. The bluing reaction on damaged tissue and a purplish-black spore print are the most reliable field indicators of Psilocybe species. Misidentification with Galerina marginata (amatoxin-containing, rusty-brown spore print) is the primary physical safety risk of wild foraging. When in doubt, do not consume.
Guidelines
Practical guidance
- Start low. Begin with 0.5–1 g dried mushroom material for a first experience. Increase only after assessing individual sensitivity.
- Weigh your dose. Use a digital scale accurate to 0.1 g. Do not estimate by visual size — potency varies 2–4-fold between individual fruiting bodies.
- Allow time. Onset takes 20–60 minutes (faster with tea or lemon tek). Do not redose before 90 minutes.
- Eat lightly beforehand. A light meal 2–3 hours before reduces nausea without significantly delaying onset.
- Prepare your environment. Remove hazards. Have water, comfortable seating, blankets, calming music, and a phone accessible.
- Plan your time. Block 6–8 hours with no obligations. Do not drive or operate machinery.
- Avoid dangerous combinations. Do not combine with MAOIs, lithium, or cannabis (especially for inexperienced users). Review Drug Interactions in the Safety section.
- Test your material. Use Ehrlich reagent at minimum. For commercial products, request or verify Certificate of Analysis where available.
Set & Setting
Set (mindset) and setting (environment) influence psilocybin experiences as powerfully as dose itself. Choose a familiar, physically safe, comfortable environment with minimal unexpected stimulation. Avoid use during periods of acute psychological distress, unresolved grief, or high anxiety — these states elevate the risk of difficult experiences.
A trusted, sober companion ("trip sitter") is strongly recommended, especially for inexperienced users or higher doses. The sitter's role is to provide calm reassurance, not to direct the experience. Clinical protocols universally include trained support personnel for this reason.
Aftercare & integration.
Post-experience processing
The hours and days following a psilocybin experience often include emotional sensitivity, fatigue, and a reflective or contemplative mood. This is normal and typically resolves within 24–48 hours.
- Hydrate and eat. Appetite may be suppressed during the experience. Rehydrate and consume a balanced meal afterward.
- Rest. Sleep may be disrupted the night of the experience. Allow extra rest the following day.
- Reflect, don't react. Significant experiences may provoke strong feelings or insights. Journaling or talking with a trusted person helps integration. Avoid making major life decisions in the immediate aftermath.
- Monitor mood. Most users report positive aftereffects for days to weeks. If persistent anxiety, depersonalisation, or visual disturbances arise, consult a healthcare professional.
Recovery & Support
Cessation and support resources
Psilocybin does not produce physical dependence or withdrawal. However, patterns of repeated use that interfere with daily functioning warrant attention and support.
- SAMHSA National Helpline: 1-800-662-4357 (US) — free, confidential, 24/7 referral service.
- Fireside Project: 62-FIRESIDE (623-473-7433) — psychedelic peer support line.
- Crisis Text Line: Text HOME to 741741 (US).
- Integration therapists: Directories at MAPS (maps.org) and Psychedelic.Support list therapists experienced in psychedelic integration.
- Tolerance management: Psilocybin's rapid tolerance (full reset in approximately 10–14 days) naturally limits frequent use. If using more often than every two weeks, consider whether the pattern serves a constructive purpose.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising and responding to a crisis
Recognise an emergency:
- Severe, escalating panic or paranoia unresponsive to reassurance
- Psychotic symptoms: delusions, loss of contact with reality, self-harm impulses
- Seizures or loss of consciousness
- Chest pain or difficulty breathing
- Suicidal statements or actions
Immediate steps:
- 1. Stay with the person. Do not leave them alone.
- 2. Speak calmly and simply: "You are safe. You took a mushroom. The effects are temporary."
- 3. Move them to a quiet, low-stimulation space if possible.
- 4. If they are overheating, cool them with water and airflow.
- 5. Call emergency services (911 / 112 / local equivalent) if: seizures occur, breathing is compromised, psychotic symptoms are severe, or the person is at risk of harming themselves or others.
What to tell the dispatcher:
- "They ingested psilocybin mushrooms" — name the substance.
- Approximate amount and time of ingestion.
- Current symptoms.
- Good Samaritan laws in many jurisdictions protect callers reporting drug emergencies from prosecution.
There is no pharmacological reversal agent for psilocybin. Benzodiazepines may be administered by medical professionals to manage severe anxiety or agitation. Time is the primary resolution — acute effects resolve within 4–8 hours.
Legal Status[edit]
Psilocybin and psilocin are Schedule I substances under the 1971 UN Convention on Psychotropic Substances, though psilocybin mushrooms themselves were not explicitly listed in the Convention text.[12] This ambiguity has allowed several jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. The legal landscape is shifting rapidly: regulated therapeutic access now exists in Oregon, Australia, and (via exemption) Canada, while federal prohibition continues in the United States, the United Kingdom, and most of Europe.
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Schedule I | Psilocybin and psilocin are Schedule I under the Controlled Substances Act (1970). DEA forwarded a rescheduling petition (Schedule I to II) in August 2025; outcome pending.[12] |
| Oregon (US) | Regulated therapeutic access | Measure 109 (2020): licensed, supervised psilocybin services. First centres opened 2023. Unregulated personal use remains illegal. |
| Colorado (US) | Decriminalised + regulated healing centres | Proposition 122 (2022): personal use, possession, cultivation, and gifting decriminalised for adults 21+. Regulated healing centres under development. |
| Other US cities | Local decriminalisation | Oakland CA, Santa Cruz CA, Ann Arbor MI, Seattle WA, Detroit MI, Northampton MA, and others have passed deprioritisation or decriminalisation measures. |
| Canada | Schedule III | Health Canada has authorised access for palliative care and therapist training via Section 56 exemptions and the Special Access Program.citation needed |
| United Kingdom | Class A | Most severe penalty classification under the Misuse of Drugs Act (1971). Research requires Home Office licence.[12] |
| Netherlands | Mushrooms banned (2008); truffles legal | Psilocybin mushrooms prohibited since 2008. Psilocybin-containing sclerotia (magic truffles) remain legal and sold in licensed smart shops.citation needed |
| Germany | Controlled (BtMG) | Schedule I analogue. Compassionate-use pathways for TRD have been authorised at select institutions.citation needed |
| Australia | Schedule 8 — Controlled Medicine | Rescheduled from Schedule 9 (effective 1 July 2023) for treatment-resistant depression only. Must be prescribed by a TGA-authorised psychiatrist; administered in a controlled medical setting with psychotherapy.[13] |
| Jamaica | Not scheduled | Psilocybin mushrooms are not prohibited under Jamaican law. Retreat centres operate legally. |
| Brazil | Not explicitly scheduled | Psilocybin is not listed as a controlled substance. Legal ambiguity exists in practice. |
The distinction between scheduled compounds (psilocybin, psilocin) and unscheduled biological material (mushrooms, truffles) under the 1971 UN Convention creates the legal space used by jurisdictions such as the Netherlands and Jamaica. National implementations vary in whether compound scheduling extends to the biological source organism or is restricted to isolated substances.
Frequently asked questions
What is Psilocybe cubensis?
Psilocybe cubensis is a psilocybin-producing fungus and the most widely cultivated psychedelic mushroom species globally. Its active metabolite psilocin acts as a 5-HT2A partial agonist, producing psychedelic effects lasting 4–8 hours when dried fruiting bodies are consumed orally.
What are dangerous combinations with Psilocybe cubensis?
The highest-severity documented interactions for Psilocybe cubensis: MAOIs (Lethal), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Psilocybe cubensis addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Psilocybe cubensis: tolerance builds rapid; full reset takes 10 days; cross-tolerance develops with LSD, mescaline, DMT, other serotonergic psychedelics. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^Kurzbaum E, Páleníček T, Shrchaton A, Azerrad SP, Dekel Y (2025) Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps — Journal of Fungi doi:10.3390/jof11020099
- [2] ^abcdSonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A (2025) Emerging mechanisms of psilocybin-induced neuroplasticity — Trends in Pharmacological Sciences doi:10.1016/j.tips.2025.08.012
- [3] ^abWinkelman M (2019) Introduction: Evidence for entheogen use in prehistory and world religions — Journal of Psychedelic Studies doi:10.1556/2054.2019.024
- [4] ^abcLowe H, Toyang NJ, Steele B, Valentine H, Grant J (2021) The Therapeutic Potential of Psilocybin — Molecules doi:10.3390/molecules26102948
- [5] ^abGriffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance — Psychopharmacology PMID:16826400
- [6] ^abcdHaijen E, Kaelen M, Roseman L, Timmermann C, Kettner H (2018) Predicting Responses to Psychedelics: A Prospective Study — Frontiers in Pharmacology doi:10.3389/fphar.2018.00897
references
- [1] ^Kurzbaum E, Páleníček T, Shrchaton A, Azerrad SP, Dekel Y (2025) Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps — Journal of Fungi doi:10.3390/jof11020099
- [2] ^abcdSonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A (2025) Emerging mechanisms of psilocybin-induced neuroplasticity — Trends in Pharmacological Sciences doi:10.1016/j.tips.2025.08.012
- [3] ^abWinkelman M (2019) Introduction: Evidence for entheogen use in prehistory and world religions — Journal of Psychedelic Studies doi:10.1556/2054.2019.024
- [4] ^abGriffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance — Psychopharmacology PMID:16826400
- [5] ^Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study — The Lancet Psychiatry doi:10.1016/s2215-0366(16)30065-7
- [6] ^abcHaijen E, Kaelen M, Roseman L, Timmermann C, Kettner H (2018) Predicting Responses to Psychedelics: A Prospective Study — Frontiers in Pharmacology doi:10.3389/fphar.2018.00897